Immatics (IMTX) Current Taxes (2023 - 2026)
Immatics (IMTX) posted Current Taxes of $2.7 million for Q4 2025, up 35.36% sequentially from $2.0 million in Q2 2025, and up 25.75% YoY from $2.1 million in Q4 2024.
Powered by 
Analysis
Immatics (IMTX) Current Taxes (2023 - 2026) Analysis & Trends
Immatics has reported Current Taxes for 2 years, with the latest figure at $2.7 million in Q4 2025.
- Quarterly Current Taxes rose 25.75% year-over-year to $2.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.7 million (up 25.75% YoY) and the FY2025 annual result came in at $2.6 million, up 20.5% from the prior year.
- Current Taxes advanced to $2.7 million in Q4 2025 per IMTX's latest filing, from $2.0 million in the prior quarter.
- Over five years, Current Taxes peaked at $2.7 million in Q4 2025 and troughed at $2.0 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 49.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 76.32 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Immatics | 1.17 Bn | 711.21 Mn | - | 969,409.79 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 969,409.79 |
| Dec 31, 2025 | 2.70 Mn |
| Jun 30, 2025 | 854,629.56 |
| Dec 31, 2024 | 2.15 Mn |
| Dec 31, 2023 | 3.83 Mn |